Synergistic Enhancement of New Bone Formation by Recombinant Human Bone Morphogenetic Protein-2 and Osteoprotegerin in Trans-Sutural Distraction Osteogenesis: A Pilot Study in Dogs

Yao, Yusheng; Wang, Guijun; Wang, Zhiying; Wang, Chengyue; Zhang, Haizhong; Liu, Chunming

doi:10.1016/j.joms.2011.07.002

Cited by 23 publications

(22 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation is in agreement with previous studies in which chitosan has been demonstrated to enhance bone growth in critical-size defects in rat, rabbit, and sheep models (Muzzarelli et al, 1994; Pang et al, 2005; Wang et al, 2002). Previous studies have also shown a significant increase in bone formation in the osseous healing area of rats, rabbits, dogs, and humans where the OPG or chitosan-based biomaterial was applied (Ezoddini-Ardakani, 2011; Florczyk et al, 2013; Jung et al, 2014; Lamoureux et al, 2007; Yao et al, 2011). Furthermore, the serum levels of markers of liver and kidney function indicated no signs of any harmful systemic effects of treatment.…”

Section: Discussionmentioning

confidence: 92%

Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit model

Jayash

Hashim

Misran

et al. 2017

PeerJ

View full text Add to dashboard Cite

BackgroundOsteoprotegerin (OPG) is used for the systemic treatment of bone diseases, although it has many side effects. The aim of this study was to investigate a newly formulated OPG-chitosan gel for local application to repair bone defects. Recent studies have reported that immunodetection of osteopontin (OPN) and osteocalcin (OC) can be used to characterise osteogenesis and new bone formation.MethodsThe osteogenic potential of the OPG-chitosan gel was evaluated in rabbits. Critical-sized defects were created in the calvarial bone, which were either left unfilled (control; group I), or filled with chitosan gel (group II) or OPG-chitosan gel (group III), with rabbits sacrificed at 6 and 12 weeks. Bone samples from the surgical area were decalcified and treated with routine histological and immunohistochemical protocols using OC, OPN, and cathepsin K (osteoclast marker) antibodies. The toxicity of the OPG-chitosan gel was evaluated by biochemical assays (liver and kidney function tests).ResultsThe mean bone growth in defects filled with the OPG-chitosan gel was significantly higher than those filled with the chitosan gel or the unfilled group (p < 0.05). At 6 and 12 weeks, the highest levels of OC and OPN markers were found in the OPG-chitosan gel group, followed by the chitosan gel group. The number of osteoclasts in the OPG-chitosan gel group was lower than the other groups. The results of the liver and kidney functional tests indicated no signs of harmful systemic effects of treatment. In conclusion, the OPG-chitosan gel has many characteristics that make it suitable for bone repair and regeneration, highlighting its potential benefits for tissue engineering applications.

show abstract

Section: Discussionmentioning

confidence: 92%

Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit model

Jayash

Hashim

Misran

et al. 2017

PeerJ

View full text Add to dashboard Cite

show abstract

“…OPG may also promote bone regeneration and enhance new bone formation (Yao et al 2011). Dialysis patients exhibit higher serum OPG levels and lower serum levels of receptor activator of nuclear factor kappa-B ligand (RANKL), most likely to compensate for higher osteoclast activity.…”

mentioning

confidence: 99%

Association between Increased Serum Osteoprotegerin Levels and Improvement in Bone Mineral Density after Parathyroidectomy in Hemodialysis Patients

Zheng

Chu

et al. 2012

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Secondary hyperparathyroidism (SHPT) is a common complication in chronic renal disease. Osteoprotegerin (OPG), an extracellular cytokine receptor secreted by osteoblasts, can promote bone formation by inhibiting the function of osteoclasts. Hemodialysis (HD) patients have elevated serum OPG levels. OPG secretion can be suppressed with high parathyroid hormone (PTH) levels. HD patients with refractory SHPT can benefit from parathyroidectomy (PTX) treatment, but the changes of serum OPG, bone turnover markers and bone mineral density (BMD) following PTX in HD patients remain unclear. In this study, patients on maintenance HD who received PTX for refractory SHPT (n = 28) were prospectively followed for 1 year. Serum intact PTH (iPTH), alkaline phosphatase (Alk-P), and OPG were measured serially; BMD was measured pre-PTX and at 1 year after PTX. After PTX, serum iPTH levels reduced profoundly. Serum Alk-P levels increased rapidly, peaking at 2 weeks post-PTX, while serum OPG levels gradually increased at 2 weeks after PTX and peaked at 2 months. BMD improved in both femoral neck (FN; cancellous and cortical bone) and lumbar spine (LS; cancellous bone). Higher baseline iPTH levels were associated with greater FN and LS BMD improvements at one year after PTX. The increment of serum OPG was correlated with the increase in LS BMD, implying that inhibition of osteoclastic bone resorption may improve BMD within the first year after PTX. These findings suggest that PTX removes the suppressive effects of high PTH on OPG secretion, resulting in the increased serum OPG levels that may contribute to BMD improvement.

show abstract

“…This may result in fibrous union or nonunion. 10,29,34 In order to enhance the quality and quantity, and the time to bone formation in DO, DO animal models were developed to test bone regeneration by MSC therapy approaches. 35 …”

Section: Discussionmentioning

confidence: 99%

Stem cell therapy for enhancement of bone consolidation in distraction osteogenesis

Yang

Lin

Wang

et al. 2017

Bone & Joint Research

View full text Add to dashboard Cite

ObjectivesDistraction osteogenesis (DO) mobilises bone regenerative potential and avoids the complications of other treatments such as bone graft. The major disadvantage of DO is the length of time required for bone consolidation. Mesenchymal stem cells (MSCs) have been used to promote bone formation with some good results.MethodsWe hereby review the published literature on the use of MSCs in promoting bone consolidation during DO.ResultsStudies differed in animal type (mice, rabbit, dog, sheep), bone type (femur, tibia, skull), DO protocols and cell transplantation methods.ConclusionThe majority of studies reported that the transplantation of MSCs enhanced bone consolidation or formation in DO. Many questions relating to animal model, DO protocol and cell transplantation regime remain to be further investigated. Clinical trials are needed to test and confirm these findings from animal studies.Cite this article: Y. Yang, S. Lin, B. Wang, W. Gu, G. Li. Stem cell therapy for enhancement of bone consolidation in distraction osteogenesis: A contemporary review of experimental studies. Bone Joint Res 2017;6:385–390. DOI: 10.1302/2046-3758.66.BJR-2017-0023.

show abstract

Synergistic Enhancement of New Bone Formation by Recombinant Human Bone Morphogenetic Protein-2 and Osteoprotegerin in Trans-Sutural Distraction Osteogenesis: A Pilot Study in Dogs

Cited by 23 publications

References 45 publications

Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit model

Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit model

Association between Increased Serum Osteoprotegerin Levels and Improvement in Bone Mineral Density after Parathyroidectomy in Hemodialysis Patients

Stem cell therapy for enhancement of bone consolidation in distraction osteogenesis

Contact Info

Product

Resources

About